Longeveron Publishes Study of Phase1 Trial Results of Lomecel-B for Alzheimer’s Disease
Mar 31, 2022 By MarketDepth
Longeveron Inc. (NASDAQ: LGVN) has announced publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease in Alzheimer’s & Dementia: The Journal of Alzheimer’s Association. The trial has met its primary endpoint as Lomecel-B was tolerated in its patient population. “We are pleased and encouraged by the publication of our study in this high-impact journal,” said Geoff Green, CEO of Longeveron. “The Lomecel-B study was funded by two competitive Part the Cloud Neuroinflammation Challenge grants awarded to Longeveron from the Alzheimer’s Association, for which we are extremely grateful.”
Alzheimer’s Clinical Trial
The article, titled “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” details the study findings on Longeveron’s lead investigational product, Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC) product, given to patients with mild Alzheimer’s disease.
“What makes this study unique is the use of a cellular therapy that may potentially target multiple pathological features of Alzheimer’s disease simultaneously. Not only did the study meet its primary endpoint of safety, but it also suggests the potential that Lomecel-B could have in treating patients with Alzheimer’s disease. We found data suggesting that Lomecel-B could have effects ranging from increasing blood vessel health to reducing inflammation, which could yield promising results.”
Dr. Mark Brody, lead author of the manuscript
